0.025-inch vs 0.035-inch guide wires for wire-guided cannulation during endoscopic retrograde cholangiopancreatography: A randomized study

Table 1 Baseline characteristics of the patients n (%)

	0.025-inch group (n = 109)	0.035-inch group (n = 160)	P value
Age, median ± IQR, year (range)	73 ± 12 (31-90)	72 ± 16 (20-97)	0.8691
Sex male/female	68/41	83/77	0.0882
Benign disease	69 (63.3)	114 (71.3)	0.1702
Choledocholithiasis	54 (49.5)	78 (48.8)	0.8992
Gallbladder stones	8 (7.3)	15 (9.4)	0.5582
Benign biliary stricture	5 (4.6)	7 (4.4)	0.8272
Cholangitis	1 (0.9)	7 (4.4)	0.2032
Others	1 (0.9)	7 (4.4)	0.2032
Malignant disease	40 (36.7)	46 (28.8)	0.1702
Pancreatic cancer	13 (11.9)	26 (16.3)	0.3232
Cholangiocarcinoma	12 (11.0)	6 (3.8)	0.0192
Gallbladder cancer	5 (4.6)	3 (1.9)	0.3582
Ampullary cancer	3 (2.8)	3 (1.9)	0.9542
Cholangiocellular carcinoma	1 (0.9)	1 (0.6)	0.6542
Others	6 (5.5)	7 (4.4)	0.8932

¹Mann-Whitney U-test;

²χ² test. IQR: Interquartile range.

Table 2 Results of selective bile duct cannulation n (%)

	0.025-inch group (n = 109)	0.035-inch group (n = 160)	P value
Success rate of selective bile duct cannulation with WGC	88 (80.7)	138 (86.3)	0.2261
Pancreatic duct GW	15 (13.8)	21 (13.1)	0.8801
Success rate of selective bile duct cannulation with pancreatic duct GW	7 (46.7)	11 (52.4)	0.8841
Precutting	9 (8.3)	11 (6.9)	0.6721
Success rate of selective bile duct cannulation with precutting	6 (66.7)	7 (63.6)	0.8931
Final success rate of selective bile duct cannulation	101 (92.7)	156 (97.5)	0.1131

¹χ² test. WGC: Wire-guided cannulation; GW: Guide wire.

Table 3 Adverse events following endoscopic retrograde cholangiopancreatography procedures n (%)

	0.025-inch group (n = 109)	0.035-inch group (n = 160)	P value
Pancreatitis	3 (2.8)	4 (2.5)	0.7931
Mild/moderate/severe, n	0/2/1	1/2/1
Bleeding	2 (1.8)	1 (0.6)	0.7371
Perforation	0%	0%
Cholangitis	0%	2 (1.3)	0.6541

¹χ² test.